Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Immuno-oncology and the future of multiple myeloma treatment

Jesús San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the emergence of chimeric antigen receptor (CAR) T-cell therapies and bispecific monoclonal antibodies, and the encouraging data being seen from trials in patients with multiple myeloma. CAR T-cell therapy and bispecific antibodies may be of particular benefit for patients that are refractory to lenalidomide. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.